Log In
BCIQ
Print this Print this
 

Acalabrutinib (ACP-196)

  Manage Alerts
Collapse Summary General Information
Company Acerta Pharma B.V.
DescriptionSecond-generation Bruton's tyrosine kinase (Btk) inhibitor
Molecular Target Bruton's tyrosine kinase (Btk)
Mechanism of ActionBruton's tyrosine kinase (Btk) inhibitor
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$7,000.0M

$2,500.0M

$1,500.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/02/2016

$7,000.0M

$2,500.0M

$1,500.0M

Get a free BioCentury trial today